Updated Jul 16, 2026
Hasnain Faheem has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $110K.
Faheem Hasnain is a prominent executive in the biopharmaceutical industry, currently serving as President and CEO of Kura Oncology, Inc. He has also held leadership roles at Gossamer Bio, Inc. and has a strong background in developing precision medicines for cancer treatment.
| Role | Insider |
|---|---|
| Notability | 50/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-12-10 | KURA | Kura Oncology, Inc. | S — Open-market sale [10b5-1] | 10.0K | $10.98 | $110K |
| 2025-12-10 | KURA | Kura Oncology, Inc. | M — Option exercise [10b5-1] | 10.0K | $3.12 | $31K |
| 2025-10-01 | GOSS | Gossamer Bio, Inc. | A — Grant or award | 437.5K | $0.00 |
Faheem Hasnain is a prominent executive in the biopharmaceutical industry, currently serving as President and CEO of Kura Oncology, Inc. He has also held leadership roles at Gossamer Bio, Inc. and has a strong background in developing precision medicines for cancer treatment.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($110K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Hasnain Faheem profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.